Literature DB >> 11406304

Release of Cr(III) from Cr(III) picolinate upon metabolic activation.

S A Kareus1, C Kelley, H S Walton, P R Sinclair.   

Abstract

Hexavalent and trivalent chromium are released into the environment from a number of different industrial activities. It is known that Cr(VI) can be reduced and subsequently complexed by humic acids to produce Cr(III) humic acid complexes in the soil and aquatic environments. The metabolic fate of Cr(III) humic acid complexes and other Cr(III) organic complexes in mammalian systems is unknown. Therefore, Cr(III) picolinate was chosen as a model complex for Cr(III) humic acid complexes and other environmentally relevant Cr(III) complexes. Both human hepatocyte microsomes and primary cultures of chick hepatocytes were used to generate metabolites of Cr(III) picolinate. The results from both of these treatments show that a significant amount of Cr(III) is released (66 and 100%, respectively) and that N-1-methylpicotinamide is the primary organic metabolite from this compound. These data suggest that the populations of humans who are exposed Cr(III) picolinate or other environmentally relevant organic Cr(III) complexes, such as Cr(III) humic acid complexes, are potentially accumulating high levels of Cr(III) intracellularly. This intracellular accumulation of Cr(III) can result in the formation of covalent bonds between Cr(III) and DNA and/or other macromolecules, causing genotoxic effects. These data should be considered when assessing the risk of an area contaminated with chromium.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406304     DOI: 10.1016/s0304-3894(01)00199-6

Source DB:  PubMed          Journal:  J Hazard Mater        ISSN: 0304-3894            Impact factor:   10.588


  5 in total

Review 1.  Chromium and genomic stability.

Authors:  Sandra S Wise; John Pierce Wise
Journal:  Mutat Res       Date:  2011-12-13       Impact factor: 2.433

2.  Chromium-picolinate therapy in diabetes care: individual outcomes require new guidelines and navigation by predictive diagnostics.

Authors:  Kristina Yeghiazaryan; Hans H Schild; Olga Golubnitschaja
Journal:  Infect Disord Drug Targets       Date:  2012-10

3.  Chromium-picolinate therapy in diabetes care: molecular and subcellular profiling revealed a necessity for individual outcome prediction, personalised treatment algorithms and new guidelines.

Authors:  Kristina Yeghiazaryan; Viktoriya Peeva; Aparna Shenoy; Hans H Schild; Olga Golubnitschaja
Journal:  Infect Disord Drug Targets       Date:  2011-04

Review 4.  The potential value and toxicity of chromium picolinate as a nutritional supplement, weight loss agent and muscle development agent.

Authors:  John B Vincent
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

5.  Opinion controversy to chromium picolinate therapy's safety and efficacy: ignoring 'anecdotes' of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan
Journal:  EPMA J       Date:  2012-10-07       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.